Article
Oncology
Isabel Beshar, Ashley S. Moon, Himani Darji, Caroline Liu, Michael T. Jennings, Oliver Dorigo, Babak Litkouhi, Elisabeth J. Diver, Amer K. Karam, Brooke E. Howitt, Malte Renz
Summary: Aberrant beta-catenin distribution is not a predictive biomarker for recurrence in early stage, low-grade endometrioid endometrial cancer.
GYNECOLOGIC ONCOLOGY
(2023)
Review
Biotechnology & Applied Microbiology
Pierluigi Giampaolino, Valeria Cafasso, Dominga Boccia, Mario Ascione, Antonio Mercorio, Francesco Viciglione, Mario Palumbo, Paolo Serafino, Cira Buonfantino, Maria Chiara De Angelis, Paolo Verrazzo, Giovanna Grasso, Giuseppe Gullo, Giuseppe Bifulco, Luigi Della Corte
Summary: Conservative treatment may be an option for patients with Stage IA G2 endometrioid endometrial cancer who desire to preserve their fertility. Evaluation of immunohistochemical markers shows promise in predicting response to conservative treatment. Further large series and randomized clinical trials are needed to confirm these results.
BIOMED RESEARCH INTERNATIONAL
(2022)
Article
Oncology
Dimitrios Nasioudis, Spyridon A. Mastroyannis, Emily M. Ko, Ashley F. Haggerty, Lori Cory, Robert L. Giuntoli, Sarah H. Kim, Nawar A. Latif
Summary: This study found that ovarian preservation is rarely performed for patients with stage I grade 2 and 3 endometrioid endometrial carcinoma undergoing hysterectomy, however, it does not have a significant negative effect on overall survival.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2022)
Article
Oncology
Zhao Liu, Jinghe Lang, Ming Wu, Lei Li
Summary: Staging surgeries should be considered in patients with apparent stage IA endometrioid endometrial carcinoma who have larger, higher grade tumors, positive lymph-vascular space invasion, or lower uterine segment involvement.
FRONTIERS IN ONCOLOGY
(2021)
Article
Pathology
Baris Boyraz, Arnaud da Cruz Paula, Kelly A. Deveraux, Ivy Tran, Edaise M. da Silva, Robert H. Young, Matija Snuderl, Britta Weigelt, Esther Oliva
Summary: We report three rare cases of endometrial/endometrioid stromal tumors with unique histologic and molecular features. These tumors exhibit specific morphologic characteristics associated with CTNNB1 translocation. This study expands the morphologic and molecular spectrum of these tumors.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY
(2023)
Article
Oncology
Dimitrios Nasioudis, Maureen Byrne, Emily M. Ko, Robert L. Giuntoli, Ashley F. Haggerty, Lori Cory, Sarah H. Kim, Mark A. Morgan, Nawar A. Latif
Summary: The study found that performing SLNBx on patients with endometrioid endometrial carcinoma did not have a negative impact on survival rates. After controlling for confounders, SLNBx showed similar survival outcomes compared to systematic lymphadenectomy. This research provides a minimally invasive option for treating these patients.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Biotechnology & Applied Microbiology
Xiaofei Liu, Junbo Zhao, Zhiwei Sun, Guangwei Wang
Summary: A retrospective analysis was conducted on data from 11,519 patients with G3 EACs to construct a nomogram for decision-making and prognosis prediction. Cox regression analysis identified age, race, tumor size, lymph node resection, stage, and adjuvant therapy as prognostic factors. The nomogram accurately predicted survival rates and will aid clinicians in managing patients more effectively.
Article
Oncology
Leonid B. Reshko, Jeremy T. Gaskins, Sara M. Dryden, Daniel S. Metzinger, Sarah L. Todd, Harriet B. Eldredge-Hindy, Scott R. Silva
Summary: The study compared the overall survival of patients with FIGO stage IB grade 3 endometrial endometrioid adenocarcinoma who underwent hysterectomy and adjuvant therapy with or without chemotherapy. Chemotherapy was associated with increased 5-year overall survival. Factors such as age, tumor size, lymph node status, race, and treatment modalities were found to impact patient survival.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2021)
Article
Oncology
Yen -Ling Lai, Chi -Son Chang, Koping Chang, Hyun-Soo Kim, Jung Chen, Wen-Fang Cheng, Yu-Li Chen, Yoo-Young Lee
Summary: This study investigated the survival benefit of combined pelvic and para-aortic lymphadenectomy compared to pelvic lymphadenectomy alone in early-stage high-grade endometrial cancer. The results showed that there was no improvement in survival for patients with FIGO stage I-II grade 3 endometrioid and non-endometrioid endometrial cancers who underwent combined pelvic and para-aortic lymphadenectomy. Therefore, para-aortic lymphadenectomy may not be necessary for these cases.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Obstetrics & Gynecology
Paul Weisman, Kay J. Park, Jin Xu
Summary: In this study, 5 cases of uterine endometrioid adenocarcinomas with high-grade divergent differentiation resembling cutaneous pilomatrix carcinoma were described. The high-grade component in these cases showed specific morphologic and immunophenotypic features, including aberrant beta-catenin and CDX2 expression, as well as loss of ER and PAX8 expression. These tumors were aggressive and showed poor prognosis in follow-up, highlighting the challenge of recognizing this phenotype at distant metastatic sites.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
(2022)
Article
Pathology
Ignacio Ruz-Caracuel, Alvaro Lopez-Janeiro, Victoria Heredia-Soto, Jorge L. Ramon-Patino, Laura Yebenes, Alberto Berjon, Alicia Hernandez, Alejandro Gallego, Patricia Ruiz, Andres Redondo, Alberto Pelaez-Garcia, Marta Mendiola, David Hardisson
Summary: The study found that CTNNB1 exon 3 mutation in low-grade, early-stage endometrioid endometrial carcinomas has a negative impact on disease-free survival, but no effect on overall survival; and nuclear beta-catenin shows better predictive value for CTNNB1 exon 3 mutation in these tumors.
Article
Oncology
Chika Nwachukwu, Mana Baskovic, Rie Von Eyben, Dylann Fujimoto, Stephanie Giaretta, Diana English, Elizabeth Kidd
Summary: In patients with early-stage endometrial cancer, time from biopsy to surgery, tumor size, and myometrial invasion are key predictors of recurrence. Patients with recurrences have lower survival rates. Identifying additional recurrence risk factors can help guide treatment decisions.
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Gregory M. Gressel, Mykhaylo Usyk, Marina Frimer, D. Y. S. Kuo, Robert D. Burk
Summary: The study found that the microbiota of postmenopausal women undergoing hysterectomy for endometrioid or uterine serous cancers differed significantly from controls with non-malignant conditions, with distinct microbial compositions in the USC group and varying functional potentials identified within different anatomical niches.
Article
Pathology
Amy Joehlin-Price, Jessica Van Ziffle, Nancy K. Hills, Nicholas Ladwig, Joseph T. Rabban, Karuna Garg
Summary: This study evaluated the prognostic impact of molecular classification on FIGO grade 3 endometrioid endometrial carcinoma, using POLE mutation analysis and immunohistochemistry. The POLE mutation group and multiple classifier group showed excellent clinical outcomes, while the p53-ab group showed the worst clinical outcomes. Overall, there was no correlation between molecular grouping and tumor immunophenotypic findings.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY
(2021)
Article
Obstetrics & Gynecology
Eda Adeviye Sahin, Serhat Toprak, Hasan Berkan Sayal, Tekin Ekinci, Ercan Yilmaz, Kadir Bakay, Rauf Melekoglu, Burak Sezgin, Yusuf Aytac Tohma, Hanifi Sahin
Summary: This study aimed to investigate the prognostic factors of G3EEC patients. LVSI was identified as an independent prognostic factor for decreased DFS and OS in G3EEC patients.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
(2022)
Article
Oncology
Dimitrios Nasioudis, Stefan Gysler, Nawar Latif, Lory Cory, Robert L. Giuntoli II, Sarah H. Kim, Fiona Simpkins, Lainie Martin, Emily M. Ko
Summary: The prevalence of ERBB2 gene amplification was investigated among patients with gynecologic malignancies. The study found that ERBB2 amplification is frequently encountered in uterine serous carcinoma and mucinous ovarian carcinoma, but less common in endometrioid endometrial carcinoma.
GYNECOLOGIC ONCOLOGY
(2024)
